Board summary
Key figures
20,930
Registered population
54.3% aged 18–64
24.3%
Aged 65+
ICB 21.9% · England 17.9%
3.4%
Ethnic minority (non-White)
1.3% Asian · England 9.6%
17.1%
In IMD quintile 1
ICB 9.2% · England 21.0%
~4,953
Core20 residents (est.)
Resident basis; registered basis ~5,584 · see page 3
5,925
Hypertension register
+3.87% in 3 yrs · England +5.60%
372
SMI register
22.9% of Wealden's
828
COPD register
Reviews -2.45% in 3 yrs
Forecast to 2030
6,792
Hypertension patients, 2030
+867 on today
65.3%
QRISK ≥20% on statins, 2030
+2.00pp over 3 yrs
6.3%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Heart failure reviews trail England by 26.0 pp.
Annual heart failure reviews fell 27.1% over 2023 to 2025 to 52.5% (England 78.5%), reaching 18.0% at Bridgeside Surgery, which may reflect recall constraints.
Phone access varies sharply across PCN practices.
Easy phone contact spans 49.6 pp from 22.2% at Bridgeside Surgery to 71.8% at Quintins Medical Centre (England 56.9%), which could reflect demand pressures.
High BP recording alongside lagging target control.
Recent BP recording reaches 92.2% (England 90.0%), though treatment to target fell 2.6% over 2023 to 2025 to 67.9% (England 70.3%), suggesting titration gaps.
Population, age and ethnicity
A population with 24.3% aged 65+ and 21.5% youth may drive dual care demand
Hailsham PCN serves 24.3% patients aged 65+ (Wealden 25.3%, NHS Sussex Integrated Care Board 21.9%, England 17.9%) and 21.5% aged 0–17 (Wealden 18.5%, NHS Sussex Integrated Care Board 17.7%, England 19.6%). Census resident ethnicity is 96.6% White (Wealden 96.0%, NHS Sussex Integrated Care Board 91.0%, England 81.1%), giving a 3.4% ethnic minority share based on Census usual residents rather than registered patients. Practice lists sum to 31,963 versus the PCN list of 20,930, creating an unresolved base discrepancy that complicates service planning.
Age profile
65+: ICB 21.9%, England 17.9%
Ethnicity
Older people · falls rows are Wealden local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wealden LA) | 2,246 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.4% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.3% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wealden LA) | 958 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wealden LA) | 8.6 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Average IMD decile of 5.7 masks a 17.1% Core20 share spanning 19.0 pp
Hailsham PCN has an average IMD decile of 5.7 (Wealden 7.1; NHS Sussex Integrated Care Board 6.1; England 5.5). Its 17.1% Core20 cohort exceeds Wealden (1.7%) and NHS Sussex Integrated Care Board (9.2%; England 21.0%). Practice shares span 19.0 pp: Quintins Medical Centre records 7.4% (1,037 estimated patients), Bridgeside Surgery 24.0% (1,642), and Hailsham Medical Group 26.3% (2,905). Practice estimates total 5,584, differing from the 4,953 resident decile 1+2 estimate. Deprivation is concentrated in two practices, meaning outreach and clinical capacity should focus on these lists first.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
372
SMI register
1.20% recorded prevalence
178
Learning disability register
0.57% recorded prevalence
17
Care homes, 684 beds
In the PCN catchment
8.8%
Provide unpaid care
Wealden, Census 2021
Recorded severe mental illness prevalence is 1.2% (372 patients; England 1.0%) and learning disability is 0.6% (178 patients; England 0.6%). Catchment care homes number 17 with 684 beds. Gypsy or Irish Traveller residents comprise 0.5% (England 0.1%). In 2025, Wealden recorded 10 rough sleepers, which cannot be extrapolated to PCN level. Care home capacity and severe mental illness registers indicate specific inclusion health coordination needs.
Severe mental illness: physical health checks
On a 1.2% SMI register, blood pressure recording is 78.2% (England 83.4%), BMI recording is 74.4% (England 82.1%) and alcohol recording is 69.0% (England 81.8%). This pattern could reflect review constraints, testable via recall audit.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,925
Hypertension register
+3.87%
Register growth, 3 yrs
Wealden +5.15% · England +5.60%
−2.20pp
BP control, under 80
≤140/90 · −0.49pp aged 80+
+867
More patients by 2030
Forecast 6,792 (20.61%)
Hypertension case-finding and control
Recorded hypertension prevalence is 19.1% (5,925 patients), above Wealden (17.7%), NHS Sussex ICB (16.3%) and England (15.2%). While recent blood pressure checks reached 92.2% (England 90.0%), treatment to target fell 2.6% over 2023 to 2025 to 67.9% (England +3.6%). For patients aged under 80, control is 64.6% (England 67.8%), spanning from 61.9% at Hailsham Medical Group and 64.4% at Bridgeside Surgery to 67.7% at Quintins Medical Centre. Crude prevalence does not establish unmet need, and denominators include personalised care adjustments. Trailing national control despite strong testing could reflect a post-check treatment gap, which clinical medication titration and recall audits would test.
Lipids and statins
Among patients with QRISK ≥ 20%, 61.1% receive lipid-lowering therapy, below England (63.6%) but above Wealden (56.8%) and NHS Sussex ICB (60.0%). Statin coverage with diabetes and cardiovascular disease is 76.7% (England 84.4%). Fewer high-risk patients receive therapy than England benchmarks, indicating a potential priority for statin initiation audits.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 49,811 | £2.80 | £2.42 | £1.86 | £139,471 |
| Cardiovascular (all), 2025 | 69,950 | £3.45 | £3.32 | £3.33 | £241,328 |
In 2026, the PCN prescribed 49,811 lipid-regulating items at £2.80 per item (England £1.86, Wealden £2.18, NHS Sussex ICB £2.42). Across 49,811 items, this is £46,822 more than at England's unit cost. This unit-cost indicator reflects formulary or case-mix differences rather than efficiency, testable via prescribing review.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+10.36%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+2.01%
Asthma prevalence, PCN 3-yr % change
Recorded COPD prevalence rose +11.1% over 2023 to 2025 to 2.7% (England 1.9%, +2.6%), but annual reviews fell 2.5% (England +2.8%) to 73.7% (England 76.4%). Asthma reviews rose +10.4% to 67.0% (England 65.7%, +4.4%) across 2,236 patients, leaving about 740 without a recorded review. Prescribing for asthma management reaches 1,711 items per 1,000 aged 5-19 (England 1,488). Diverging register growth and falling reviews may indicate review capacity constraints, testable via recall audit.
Cancer register and children's immunisation
Cancer prevalence is 5.3% (1,642 patients; England 3.8%). In Q1 2025/26, childhood 6-in-1 coverage at 12 months reached 100.0% (England 91.0%). Age-five MMR coverage dropped by 6.1 pp between dose 1 (96.9%) and dose 2 (90.8%), sitting 4.2 pp below the 95.0% target. This could reflect recall timing gaps, testable by checking practice reminder logs. Supplementary COVER data reflects small quarterly cohorts (65 children), representing rate differences rather than individual dropouts.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
58.5%
Sussex ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~1,360
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Sussex ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 56.6% | 53.2% | 19% | 1,668 |
| Breast | 86.1% | 85.4% | 23% | 1,400 |
| Bowel | 49.8% | 47.0% | 26% | 1,133 |
| Lung | 30.3% | 33.8% | 15% | 1,058 |
| Skin cancer | 95.3% | 87.8% | 17% | 698 |
In 2022, 58.5% of staged cancers across NHS Sussex ICB were diagnosed at stage 1 or 2 (4,799 of 8,209 known-stage cases), 3.2 percentage points above England (55.3%) but 16.5 pp below the 75.0% national ambition by 2028. Known stage was recorded for 64.3% of 12,766 registered cancers (England 67.0%). Achieving 75.0% requires about 1,360 additional early diagnoses annually across the ICB. PCN cervical screening coverage is 71.3% (England 66.8%), though Hailsham Medical Group records 66.0%. These ICB data reflect wider system activity rather than PCN delivery. Cervical screening uptake variations may leave eligible cohorts under-screened, warranting focused recall.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), East Sussex Healthcare NHS Trust achieved 67.0% on the cancer 62-day referral to treatment standard, 18.0 pp below the 85.0% standard. Among nearest trusts, Maidstone and Tunbridge Wells NHS Trust reached 87.4% and University Hospitals Sussex NHS Foundation Trust achieved 65.2%, compared with NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). On the 28-day faster diagnosis standard, East Sussex Healthcare NHS Trust reached 84.2% (standard 75.0%; ICB 79.3%; England 79.3%). For all diagnostic tests, 5.3% waited 6+ weeks at the trust (England 23.1%).
| Pathways within standard (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 84.20 | 74.01 | 81.78 | 79.29 | 79.32 |
| 31-day treatment (96%) | 98.19 | 76.79 | 98.35 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 67.04 | 65.20 | 87.43 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | East Sussex Healthcare | Sussex | Maidstone and Tunbridge Wells | England |
|---|---|---|---|---|
| MRI | 6.48 | 5.62 | 0.92 | 21.40 |
| CT | 0.48 | 8.57 | 0.51 | 9.92 |
| Echocardiography | 21.94 | 0.39 | 2.57 | 28.48 |
| Colonoscopy | 0.74 | 39.35 | 19.80 | 30.83 |
| Gastroscopy | 0.31 | 20.02 | 24.03 | 29.02 |
| All 15 DM01 tests | 5.27 | 12.95 | 6.42 | 23.14 |
| Community services activity | East Sussex residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 100,740 | 309,615 |
| Referrals | 17,285 | 66,930 |
| Patients with a contact | 25,880 | 85,660 |
Community services (residents of East Sussex), Jun 2026 (provisional). In Jun 2026 (provisional), East Sussex recorded 105,045 community care activities and 100,740 care contacts across 25,880 patients, with adults aged 65+ accounting for 68% of contacts. Across NHS Surrey and Sussex Integrated Care Board, 316,320 care activities and 309,615 contacts were recorded. These experimental resident figures describe wider system activity, showing substantial community contact volume among older residents.
Practice variation and patient experience
Phone contact spans 49.6 pp and vaccination achievement spans 50.2 pp across practices
In 2025/26, QOF overall achievement ranged from 90.2% at Bridgeside Surgery and 90.9% at Hailsham Medical Group to 100.0% at Quintins Medical Centre (England calculated 92.5%). Vaccination and immunisation achievement spanned 50.2 pp, from 49.8% at Hailsham Medical Group and 92.4% at Bridgeside Surgery to 100.0% at Quintins Medical Centre (England calculated 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Quintins | 108 | 7.4 | 71.8% | 82.0% | 76.8% |
| Hailsham Medical | 101 | 26.3 | 44.2% | 54.2% | 68.6% |
| Bridgeside Surgery | 92 | 24.0 | 22.2% | 63.4% | 61.0% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Fifteen of 25 measures trail England's three-year change, led by heart failure reviews
Across 25 compared measures, 15 trail England's three-year change. The widest lag is in annual heart failure reviews, which fell 27.1% over 2023 to 2025 to 52.5% (England rose +8.7% to 78.5%), dropping to 18.0% at Bridgeside Surgery. Alcohol recording for patients with psychosis also fell 5.3 pp to 69.0% (England rose +5.4 pp to 81.8%). Conversely, three-year relative progress exceeded England in asthma reviews (+10.4% vs +4.4%), breast screening coverage (+11.8% vs +8.4%) and diabetes HbA1c control without frailty (+6.2% vs +4.4%).
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
Alcohol record (psychosis)
BP control, under 80
Hypertension treated to target
COPD reviews
Asthma reviews
Breast screening (53-70)
Diabetes HbA1c control
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wealden | Asset | PCN | Wealden |
|---|---|---|---|---|---|
| Care homes (catchment) | 17 (684 beds) | n/a | Schools (catchment) | 25 | n/a |
| Children's centres | 1 | 2 | Places of worship | 32 | 161 |
| Libraries | 1 | 7 | Food banks (VCS) | n/a | 1 |
| Homelessness support (VCS) | 2 | 2 | Day centres (VCS) | n/a | 6 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 5 | 40 | Primary academies | 5 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension titration and recall review
On a 5,925-patient register (19.1% prevalence), treatment to target fell 2.6% over 2023 to 2025 to 67.9% (England 70.3%, +3.6%); control under 80 is 64.6% (England 67.8%), with 61.9% at Hailsham Medical Group and 64.4% at Bridgeside Surgery. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Combined SMI physical health checks
Across 372 patients (1.2% prevalence), BP recording is 78.2% (+0.5 pp over 2023 to 2025; England 83.4%, +4.4 pp), BMI is 74.4% (England 82.1%) and alcohol recording fell 5.3 pp to 69.0% (England 81.8%, +5.4 pp). For discussion: introduce a combined check template, care-coordinator outreach, and shared partner recording pathways. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Core20 access and review alignment
Easy phone contact spans 49.6 pp (22.2% at Bridgeside Surgery, 44.2% at Hailsham Medical Group, 71.8% at Quintins Medical Centre; England 56.9%), while heart failure reviews fell 27.1% to 52.5% across 379 patients (England 78.5%, +8.7%). Moderate effort to run.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Practice list reconciliation (p2) | Aged 65+ · Aged 0-17 | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical check recall (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school MMR recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension titration and recall review (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
| Option 3 · Core20 access and review alignment (p12) | Core20 cohort (IMD quintile 1) · GPPS easy to contact the practice by phone · GPPS survey response rate | — | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
